News - Otsuka, Nephrology and Hepatology


Popular Filters

Otsuka's Samsca gains additional indication in Japan


Japanese drugmaker Otsuka (TYO: 4768) says that its vasopressin V2 receptor antagonist Samsca (tolvaptan)…

Asia-PacificNephrology and HepatologyOtsukaPharmaceuticalRegulationSamscatolvaptan

Setback for Otsuka's tolvaptan


The US subsidiary of Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) has received a Complete Response…

Nephrology and HepatologyOtsukaPharmaceuticalRegulationRest of the Worldtolvaptan

Negative advisory view for Otsuka's tolvaptan in ADPKD


Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) says that the US Food and Drug Administration's…

Nephrology and HepatologyNorth AmericaOtsukaPharmaceuticalRegulationtolvaptin

US FDA accepts NDAs for Otsuka's tolvaptan and BTG's Varisolve


Japanese mid-sized drugmaker Otsuka Pharmaceutical (TYO: 4578) says that the US Food and Drug Administration…

BTGCardio-vascularNephrology and HepatologyNorth AmericaOtsukaPharmaceuticalRare diseasesRegulationtolvaptanVarisolve

ASN meeting highlights Otsuka's tolvaptan' Alexion's Solaris and Roche's aleglitazar research


Japan's Otsuka Pharmaceutical (TYO: 4768) that the clinical trial results for tolvaptan, an investigational…

aleglitazarAlexion PharmaceuticalsNephrology and HepatologyOtsukaPharmaceuticalResearchRocheSolaristolvaptan

Japanese filings for Shionogi's metreleptin and Otsuka's tolvaptin


Japanese drugmaker Shionogi (TYO: 4507) said last week that it has filed a New Drug Application with…

Asia-PacificmetreleptinNephrology and HepatologyOtsukaPharmaceuticalRare diseasesRegulationSamscaShionogitolvaptin

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top